多西他赛、阿霉素和环磷酰胺治疗的乳腺癌患者使用低剂量非格司亭的情况。

Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.

作者信息

Ip Eric J, Lee-Ma Annette, Troxell Lawrence S, Chan James

机构信息

Department of Clinical Sciences, Touro University College of Pharmacy, Vallejo, CA 94592, USA.

出版信息

Am J Health Syst Pharm. 2008 Aug 15;65(16):1552-5. doi: 10.2146/ajhp070489.

DOI:10.2146/ajhp070489

PMID:18693211

Abstract

PURPOSE

The objective of this study was to compare low-dose filgrastim (150 microg/day subcutaneously) with standard-dose subcutaneous filgrastim (300 microg/day) or lenograstim (263 microg/day) in preventing febrile neutropenia and hospitalizations in breast cancer patients receiving the docetaxel-doxorubicin-cyclophosphamide regimen.

METHODS

A single-center retrospective data analysis was performed involving 22 adult women with breast cancer who concurrently received the docetaxel-doxorubicin-cyclophosphamide chemotherapy regimen and low-dose filgrastim from March 2004 to February 2007. Data from this study were compared to previously published data in which patients received standard-dose filgrastim or lenograstim.

RESULTS

More patients developed febrile neutropenia in the low-dose filgrastim group compared with the standard-dose group (32% versus 7.5%, respectively; p = 0.0014; relative risk [RR] = 4.24; 95% confidence interval [CI], 2.04-7.83). More patients were hospitalized due to febrile neutropenia in the low-dose filgrastim group compared with the standard-dose group (32% versus 6.5%, respectively; p < 0.001; RR = 4.89; 95% CI, 2.32-9.13). More chemotherapy cycles resulted in febrile neutropenia in the low-dose filgrastim group compared with the standard-dose group (6.7% versus 1.2%, respectively; p < 0.001; RR = 5.58; 95% CI, 2.49-12.27).

CONCLUSION

In patients with breast cancer treated with the docetaxel-doxorubicin-cyclophosphamide regimen, low-dose filgrastim was associated with a higher frequency of febrile neutropenia, hospitalization due to febrile neutropenia, and cycles with febrile neutropenia compared with a historical control group treated with standard-dose filgrastim or lenograstim.

摘要

目的

本研究的目的是比较低剂量非格司亭（皮下注射150微克/天）与标准剂量皮下注射非格司亭（300微克/天）或来格司亭（263微克/天）在接受多西他赛-阿霉素-环磷酰胺方案治疗的乳腺癌患者中预防发热性中性粒细胞减少症和住院情况。

方法

进行了一项单中心回顾性数据分析，纳入了22名成年乳腺癌女性患者，她们在2004年3月至2007年2月期间同时接受多西他赛-阿霉素-环磷酰胺化疗方案和低剂量非格司亭治疗。将本研究的数据与先前发表的患者接受标准剂量非格司亭或来格司亭治疗的数据进行比较。

结果

与标准剂量组相比，低剂量非格司亭组发生发热性中性粒细胞减少症的患者更多（分别为32%和7.5%；p = 0.0014；相对危险度[RR]=4.24；95%置信区间[CI]，2.04 - 7.83）。与标准剂量组相比，低剂量非格司亭组因发热性中性粒细胞减少症住院的患者更多（分别为32%和6.5%；p < 0.001；RR = 4.89；95%CI，2.32 - 9.13）。与标准剂量组相比，低剂量非格司亭组更多的化疗周期导致发热性中性粒细胞减少症（分别为6.7%和1.2%；p < 0.001；RR = 5.58；95%CI，2.49 - 12.27）。